Allergic Conjunctivitis in Vernal Keratoconjunctivitis or Atopic Conjunctivitis
This protocol covers the management of allergic conjunctivitis in patients with a confirmed diagnosis of vernal keratoconjunctivitis (VKC) or atopic conjunctivitis.
Clinical Scenario
Patients present with allergic conjunctivitis in the specific setting of vernal keratoconjunctivitis or atopic conjunctivitis. General measures include modifying the environment to minimize exposure to allergens or irritants, along with cool compresses and ocular lubricants.
Treatment Approach
During acute exacerbations, topical anti-inflammatory therapy is typically required to bring severe symptoms and signs under control. For severe vernal keratoconjunctivitis or atopic conjunctivitis, topical cyclosporine preparations represent an important part of the management strategy.
The complete regimen — including specific agents, concentrations, sequencing, and monitoring criteria — is contained in the full structured protocol.
Treatment Goal
The clinical target is a reduction in signs and symptoms following topical cyclosporine therapy, with use of cyclosporine offering the potential to reduce reliance on topical corticosteroids.
References
- General treatment measures for vernal/atopic conjunctivitis include modifying the environment to minimize exposure to allergens or irritants and using cool compresses and ocular lubricants.
- For acute exacerbations of vernal/atopic conjunctivitis, topical corticosteroids are usually necessary to control severe symptoms and signs.
- Topical cyclosporine 2% has demonstrated a reduction in signs and symptoms compared with placebo after two weeks of use in patients with VKC.
- Commercially available 0.05% topical cyclosporine has also been shown to be effective in more frequent dosing for the treatment of severe vernal/atopic conjunctivitis and it has been shown to be effective in preventing seasonal recurrences.
- Use of cyclosporine may allow for reduced use of topical steroids.
View source ↗